Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 5/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1655534 | 0.88 | ALDH1A1 (0.46) | ALDH1A1KDM4EPOLBNR1H2ATM | |
| SCHEMBL27081642 | 0.86 | KDM4E (0.48) | ALDH1A1KDM4EPOLBNR1H2ATM | |
| SCHEMBL28001279 | 0.82 | KDM4E (0.42) | ALDH1A1KDM4EPOLBNR1H2ATM | |
| SCHEMBL16463965 | 0.82 | CYP2A13 (0.45) | ALDH1A1KDM4EPOLBNR1H2ATM | |
| SCHEMBL27677146 | 0.82 | ALDH1A1 (0.52) | ALDH1A1KDM4EPOLBNR1H2ATM | |
| SCHEMBL14318329 | 0.78 | ALDH1A1 (0.88) | ALDH1A1KDM4EPOLBNR1H2ATM | |
| SCHEMBL28816963 | 0.76 | MLNR (0.42) | ALDH1A1KDM4EPOLBNR1H2ATM | |
| SCHEMBL28001612 | 0.76 | MLNR (0.42) | ALDH1A1KDM4EPOLBNR1H2ATM | |
| SCHEMBL347003 | 0.76 | DDR1 (0.42) | ALDH1A1KDM4EABL1 | |
| SCHEMBL7923610 | 0.75 | NR1H2 (0.72) | ALDH1A1KDM4EPOLBNR1H2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111777592-B | N4- (2, 5-dimethoxyphenyl) -pyrimidinediamine targeted DDR1 inhibitor and preparation and application thereof | 温州医科大学 | 2021-06-18 | — | — | CN | claimed |
| CN-111793035-B | N4- (3-methoxyphenyl) -pyrimidinediamine targeted DDR1 inhibitor and preparation and application thereof | 温州医科大学 | 2021-06-18 | — | — | CN | claimed |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-07-04 | — | — | US | disclosed |
| US-20240190847-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-13 | — | — | US | disclosed |
| EP-4313292-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313972-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-02-07 | — | — | EP | disclosed |
| CN-117120434-A | Indoline derivatives as DDR1 and DDR2 inhibitors | 奇斯药制品公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117062812-A | Indoline derivatives as DDR inhibitors | 奇斯药制品公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-110194772-A | For inhibiting (miscellaneous) the fragrant cyclics of the alkynyl of protein kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2019-09-03 | — | — | CN | disclosed |
| CN-102548987-B | Fluoro-substituted compounds as kinase inhibitors and methods of use thereof | MEDOLUTION LTD JIANGSU CHINA | 2014-04-16 | — | — | CN | disclosed |
| CN-102548987-A | Fluoro-substituted compounds as kinase inhibitors and methods of use thereof | MEDOLUTION LTD | 2012-07-04 | — | — | CN | disclosed |
| WO-2011008788-A1 | FLUORO-SUBSTITUTED COMPOUNDS AS KINASE INHIBITORS AND METHODS OF USE THEREOF | ZHANG DAWEI (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190847-A1 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | DDR1, DDR2, DDRGK1 | ALDH1A1 2364/4885KDM4E 2415/4885POLB 2296/4885 |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | DDR1, DDR2, DDRGK1 | ALDH1A1 3751/4885KDM4E 2592/4885POLB 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.